PH12014501491A1 - Subcutaneous therapeutic use of dpp-4 inhibitor - Google Patents
Subcutaneous therapeutic use of dpp-4 inhibitorInfo
- Publication number
- PH12014501491A1 PH12014501491A1 PH12014501491A PH12014501491A PH12014501491A1 PH 12014501491 A1 PH12014501491 A1 PH 12014501491A1 PH 12014501491 A PH12014501491 A PH 12014501491A PH 12014501491 A PH12014501491 A PH 12014501491A PH 12014501491 A1 PH12014501491 A1 PH 12014501491A1
- Authority
- PH
- Philippines
- Prior art keywords
- inhibitor
- dpp
- subcutaneous
- therapeutic use
- subcutaneous therapeutic
- Prior art date
Links
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 title abstract 3
- 238000007920 subcutaneous administration Methods 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11196122 | 2011-12-29 | ||
| EP12169267 | 2012-05-24 | ||
| PCT/EP2012/077024 WO2013098372A1 (en) | 2011-12-29 | 2012-12-28 | Subcutaneous therapeutic use of dpp-4 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12014501491A1 true PH12014501491A1 (en) | 2014-09-22 |
Family
ID=47470023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12014501491A PH12014501491A1 (en) | 2011-12-29 | 2014-06-27 | Subcutaneous therapeutic use of dpp-4 inhibitor |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130172244A1 (enExample) |
| EP (1) | EP2797589A1 (enExample) |
| JP (1) | JP6198015B2 (enExample) |
| KR (1) | KR20140107342A (enExample) |
| CN (1) | CN104136014A (enExample) |
| AU (1) | AU2012360878A1 (enExample) |
| BR (1) | BR112014015955A8 (enExample) |
| CA (1) | CA2861778A1 (enExample) |
| CL (1) | CL2014001587A1 (enExample) |
| EA (1) | EA201400767A1 (enExample) |
| IL (1) | IL232588A0 (enExample) |
| MX (1) | MX2014007768A (enExample) |
| PH (1) | PH12014501491A1 (enExample) |
| WO (1) | WO2013098372A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| EP2382216A1 (en) | 2008-12-23 | 2011-11-02 | Boehringer Ingelheim International GmbH | Salt forms of organic compound |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| EP3646859A1 (en) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| AU2011249722B2 (en) | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
| CN106975074A (zh) | 2010-06-24 | 2017-07-25 | 勃林格殷格翰国际有限公司 | 糖尿病治疗 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| PH12014500137A1 (en) | 2011-07-15 | 2017-08-18 | Boehringer Ingelheim Int | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| US20130303554A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in sirs and/or sepsis |
| EP2854812A1 (en) * | 2012-05-24 | 2015-04-08 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada |
| WO2013174767A1 (en) * | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| CN104548096B (zh) * | 2013-10-09 | 2019-09-10 | 深圳翰宇药业股份有限公司 | 一种含有glp-1类似物和dpp-4抑制剂的药物组合物及其制备方法 |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| TWI748945B (zh) * | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| KR102644400B1 (ko) | 2015-04-28 | 2024-03-06 | 바스프 에이에스 | 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도 |
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| US11925614B2 (en) | 2017-12-06 | 2024-03-12 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| EP4415720A4 (en) * | 2021-10-17 | 2025-07-30 | Zenvision Pharma Llp | NEW PARENTERAL COMPOSITION COMPRISING LINAGLIPTIN OR ITS SALTS |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0305387B2 (en) * | 1986-05-05 | 1996-08-28 | The General Hospital Corporation | Insulinotropic hormone |
| US5120712A (en) * | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| TW225528B (enExample) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| EP0941114B1 (en) * | 1996-11-12 | 2005-02-23 | Novo Nordisk A/S | Use of glp-1 peptides |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| MXPA03007349A (es) | 2001-02-24 | 2003-12-04 | Boehringer Ingelheim Pharma | Derivados de xantina, su preparacion y su empleo como medicamentos. |
| EP1474163A2 (en) * | 2002-01-10 | 2004-11-10 | Imperial College Innovations Limited | Modification of feeding behavior |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| DK1532149T3 (da) | 2002-08-21 | 2010-05-10 | Boehringer Ingelheim Pharma | 8-[3-amino-piperiden-1-yl]-xanthiner, fremstilling deraf og anvendelse deraf som lægemiddel |
| DE10238477A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10238470A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10251927A1 (de) | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10254304A1 (de) | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| UY28103A1 (es) | 2002-12-03 | 2004-06-30 | Boehringer Ingelheim Pharma | Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos |
| DE10327439A1 (de) | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10355304A1 (de) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10359098A1 (de) | 2003-12-17 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10360835A1 (de) | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel |
| BRPI0507873B8 (pt) | 2004-02-18 | 2021-05-25 | Boehringer Ingelheim Int | 8-[3-amino-piperidin-1-il]-xantinas, seu processo de produção, seu uso como inibidor de dpp-iv e medicamento |
| DE102004009039A1 (de) | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel |
| CA2561210A1 (en) | 2004-04-10 | 2005-10-20 | Boehringer Ingelheim International Gmbh | Novel 2-amino-imidazo[4,5-d]pyridazin-4-ones and 2-amino-imidazo[4,5-c]pyridin-4-ones, production and use thereof as medicaments |
| DE102004022970A1 (de) | 2004-05-10 | 2005-12-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazolderivate, deren Herstellung und deren Verwendung als Intermediate zur Herstellung von Arzneimitteln und Pestiziden |
| DE102004043944A1 (de) | 2004-09-11 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004044221A1 (de) | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| MX2007004021A (es) | 2004-10-08 | 2007-05-24 | Novartis Ag | Combinacion de compuestos organicos. |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| MX2007007483A (es) | 2004-12-24 | 2007-07-20 | Dainippon Sumitomo Pharma Co | Derivados de pirroles biciclicos. |
| JP2008536881A (ja) * | 2005-04-21 | 2008-09-11 | ガストロテック・ファルマ・アクティーゼルスカブ | Ｇｌｐ−１分子と制吐剤との医薬製剤 |
| CA2612142A1 (en) | 2005-07-01 | 2007-01-11 | Merck & Co., Inc. | Process for synthesizing a cetp inhibitor |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| CN101384594A (zh) | 2005-12-23 | 2009-03-11 | 诺瓦提斯公司 | 用作dpp-iv抑制剂的稠合杂环化合物 |
| MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| WO2008017670A1 (en) | 2006-08-08 | 2008-02-14 | Boehringer Ingelheim International Gmbh | Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus |
| PE20090696A1 (es) * | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EA029759B1 (ru) * | 2009-02-13 | 2018-05-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами |
| EP2395983B1 (en) * | 2009-02-13 | 2020-04-08 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
| EP3646859A1 (en) * | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| AU2011249722B2 (en) * | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
| AR083878A1 (es) * | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
-
2012
- 2012-12-27 US US13/727,667 patent/US20130172244A1/en not_active Abandoned
- 2012-12-28 KR KR1020147018004A patent/KR20140107342A/ko not_active Withdrawn
- 2012-12-28 CN CN201280070830.0A patent/CN104136014A/zh active Pending
- 2012-12-28 MX MX2014007768A patent/MX2014007768A/es unknown
- 2012-12-28 EA EA201400767A patent/EA201400767A1/ru unknown
- 2012-12-28 BR BR112014015955A patent/BR112014015955A8/pt not_active IP Right Cessation
- 2012-12-28 WO PCT/EP2012/077024 patent/WO2013098372A1/en not_active Ceased
- 2012-12-28 CA CA2861778A patent/CA2861778A1/en not_active Abandoned
- 2012-12-28 EP EP12808849.9A patent/EP2797589A1/en not_active Withdrawn
- 2012-12-28 JP JP2014549477A patent/JP6198015B2/ja active Active
- 2012-12-28 AU AU2012360878A patent/AU2012360878A1/en not_active Abandoned
-
2014
- 2014-05-13 IL IL232588A patent/IL232588A0/en unknown
- 2014-06-16 CL CL2014001587A patent/CL2014001587A1/es unknown
- 2014-06-27 PH PH12014501491A patent/PH12014501491A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012360878A1 (en) | 2014-06-05 |
| NZ624972A (en) | 2016-07-29 |
| CL2014001587A1 (es) | 2014-12-05 |
| EP2797589A1 (en) | 2014-11-05 |
| CA2861778A1 (en) | 2013-07-04 |
| US20130172244A1 (en) | 2013-07-04 |
| WO2013098372A1 (en) | 2013-07-04 |
| JP6198015B2 (ja) | 2017-09-20 |
| KR20140107342A (ko) | 2014-09-04 |
| MX2014007768A (es) | 2014-09-22 |
| IL232588A0 (en) | 2014-06-30 |
| JP2015503539A (ja) | 2015-02-02 |
| EA201400767A1 (ru) | 2014-12-30 |
| BR112014015955A8 (pt) | 2017-07-04 |
| BR112014015955A2 (pt) | 2017-06-13 |
| CN104136014A (zh) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501491A1 (en) | Subcutaneous therapeutic use of dpp-4 inhibitor | |
| PH12012502524A1 (en) | Diabetes therapy | |
| PH12012502162A1 (en) | Combination therapy | |
| PH12014501997A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| GB201111485D0 (en) | Drug composition and its use in therapy | |
| EP2582682A4 (en) | METHOD FOR THE TREATMENT OF LUNG DISEASES | |
| MX2014002395A (es) | Inhibidores de rock suaves, novedosos. | |
| BR112013020798A2 (pt) | terapia de combinação do inibidor mtor /jak | |
| MY156243A (en) | Treatment for diabetes in patients inappropriate for metformin therapy | |
| PH12013500618A1 (en) | Therapeutic use of a tlr agonist and combination therapy | |
| MX365950B (es) | Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica. | |
| PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| EA033067B1 (ru) | Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения | |
| PH12013500543A1 (en) | Breast cancer therapeutics | |
| PH12012502129A1 (en) | New combination therapy in treatment of oncological and fibrotic diseases | |
| EA201370230A1 (ru) | Новые ингибиторы rock | |
| MX362485B (es) | Nuevos inhibidores de rock. | |
| MX2013008715A (es) | Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco. | |
| EA201490199A8 (ru) | Терапевтические способы | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol | |
| WO2011163231A3 (en) | Combination therapy for the treatment of diabetes | |
| TN2013000336A1 (en) | 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy. | |
| GB201111427D0 (en) | Novel bisindolylmaleimides, pan-pkc inhibitors | |
| TN2011000060A1 (en) | Treatment for diabetes in patients inappropriate for metformin therapy | |
| UA67427U (ru) | Способ лечения фиброзно-кавернозных форм органного туберкулеза |